Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study.
Publication
, Conference
Hirohashi, T; Beck, JT; McDermott, JD; Abbruzzese, JL; Doi, T; Ingram, K; Li, R; Subbiah, V
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hirohashi, T., Beck, J. T., McDermott, J. D., Abbruzzese, J. L., Doi, T., Ingram, K., … Subbiah, V. (2023). Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Hirohashi, Tomoko, Joseph Thaddeus Beck, Jessica Dreger McDermott, James L. Abbruzzese, Toshihiko Doi, Kim Ingram, Ruifeng Li, and Vivek Subbiah. “Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Hirohashi T, Beck JT, McDermott JD, Abbruzzese JL, Doi T, Ingram K, et al. Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Hirohashi, Tomoko, et al. “Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.
Hirohashi T, Beck JT, McDermott JD, Abbruzzese JL, Doi T, Ingram K, Li R, Subbiah V. Trials in progress: TAM kinase inhibitor PF-07265807 and sasanlimab plus axitinib in patients with advanced or metastatic renal cell carcinoma-A phase 1, open-label, pharmacokinetic, safety and tolerability study. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences